Johnson and Johnson subsidiary to team up with University of Queensland spin-out to treat rheumatoid arthritis.
Dendright Pty, a biotech spin-out from the University of Queensland (UQ), has announced a collaboration with Johnson and Johnson subsidiary Janssen Biotech to tackle rheumatoid arthritis.
As part of the deal, the two will work together to move a new treatment, based on research from UQ’s Diamantina Institute, for the condition towards Phase I clinical trials. The deal is part of a developing relationship between the two firms after Janssen provided Dendright with seed financing last year.
The treatment differs…
